Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Cidara Therapeutics initiated with a Buy at Maxim » 08:44
03/10/20
03/10
08:44
03/10/20
08:44
CDTX

Cidara Therapeutics

$2.66 /

-0.24 (-8.28%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy initiated coverage of Cidara Therapeutics with a Buy rating and $10 price target. The analyst believes that the company's long-acting drug rezafungin could emerge as a best-in-class option in the $1.1B echinocandin market, while also expanding into the broader over-$4B antifungal market. McCarthy further cites Cidara's strong balance sheet and potential phase 3 data catalysts expected in the first half of 20201.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Cidara Therapeutics initiated with a Buy at Maxim » 07:55
03/10/20
03/10
07:55
03/10/20
07:55
CDTX

Cidara Therapeutics

$2.66 /

-0.24 (-8.28%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy initiated coverage of Cidara Therapeutics with a Buy rating and $10 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Earnings
Cidara Therapeutics reports Q4 EPS (42c), consensus (43c) » 05:57
03/04/20
03/04
05:57
03/04/20
05:57
CDTX

Cidara Therapeutics

$2.86 /

-0.11 (-3.70%)

Reports Q4 revenue $1.8M,…

Reports Q4 revenue $1.8M, may not compare to consensus $3.63M. "2019 was a transformational year for Cidara, as we achieved multiple key corporate and clinical milestones," said Jeffrey Stein, Ph.D., president and CEO of Cidara. "In July 2019 we released positive top line data from our STRIVE B clinical trial which was followed in September with the announcement of our partnership with Mundipharma for the ex-U.S. and ex-Japan rights to rezafungin. We also announced the nomination of our Cloudbreak development candidate, CD377, which we plan to develop as the first antiviral drug conjugate (AVC) with the potential for universal, once-per-season prevention, as well as treatment of influenza. The significant momentum our business generated in 2019 continued into early 2020, as we recently raised $30 million via a rights offering that was fully backstopped by BVF Partners and Stonepine Capital. Looking ahead, we continue to enroll patients in our pivotal Phase 3 ReSTORE treatment trial and we will initiate our Phase 3 ReSPECT prophylaxis study."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/23/20
02/23
04:55
02/23/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/22/20
02/22
04:55
02/22/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/21/20
02/21
04:55
02/21/20
04:55
ABBV

AbbVie

$94.26 /

+0.13 (+0.14%)

, ADPT

Adaptive Biotechnologies

$33.82 /

+0.28 (+0.83%)

, AMGN

Amgen

$222.18 /

-0.94 (-0.42%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0011 (+0.44%)

, ATRA

Atara Biotherapeutics

$13.52 /

-1.23 (-8.34%)

, AZN

AstraZeneca

$48.97 /

-0.34 (-0.69%)

, BLUE

Bluebird Bio

$82.53 /

+1.98 (+2.46%)

, CDNA

CareDx

$28.12 /

-0.05 (-0.18%)

, CDTX

Cidara Therapeutics

$3.16 /

-0.01 (-0.32%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.10 /

+0.04 (+0.79%)

, GMDA

Gamida Cell

$4.75 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$42.76 /

+0.4688 (+1.11%)

, HUM

Humana

$371.55 /

-7.115 (-1.88%)

, INCY

Incyte

$82.77 /

+0.32 (+0.39%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.05 /

-0.085 (-1.66%)

, MGTA

Magenta Therapeutics

$14.02 /

+0.91 (+6.94%)

, MRK

Merck

$82.48 /

+0.48 (+0.59%)

, NVS

Novartis

$96.31 /

-0.98 (-1.01%)

, PFE

Pfizer

$35.84 /

-0.39 (-1.08%)

, RCKT

Rocket Pharmaceuticals

$23.74 /

-0.26 (-1.08%)

, SGEN

Seattle Genetics

$118.30 /

-1.6 (-1.33%)

, SNY

Sanofi

$50.76 /

+0.06 (+0.12%)

, TAK

Takeda Pharmaceutical

$18.59 /

-0.43 (-2.26%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/20/20
02/20
04:55
02/20/20
04:55
ABBV

AbbVie

$94.13 /

+0.53 (+0.57%)

, ADPT

Adaptive Biotechnologies

$33.54 /

+1.79 (+5.64%)

, AMGN

Amgen

$223.12 /

+1.38 (+0.62%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0041 (+1.67%)

, ATRA

Atara Biotherapeutics

$14.75 /

+0.2 (+1.37%)

, AZN

AstraZeneca

$49.31 /

+0.14 (+0.28%)

, BLUE

Bluebird Bio

$80.55 /

-7.61 (-8.63%)

, CDNA

CareDx

$28.17 /

+1.02 (+3.76%)

, CDTX

Cidara Therapeutics

$3.17 /

+0.09 (+2.92%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.06 /

+0.02 (+0.40%)

, GMDA

Gamida Cell

$4.75 /

-0.01 (-0.21%)

, GSK

GlaxoSmithKline

$43.49 /

-0.06 (-0.14%)

, HUM

Humana

$378.67 /

+6.41 (+1.72%)

, INCY

Incyte

$82.45 /

+3.2 (+4.04%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.13 /

+0.285 (+5.88%)

, MGTA

Magenta Therapeutics

$13.11 /

+0.55 (+4.38%)

, MRK

Merck

$82.00 /

-0.46 (-0.56%)

, NVS

Novartis

$97.29 /

+0.08 (+0.08%)

, PFE

Pfizer

$36.23 /

-0.08 (-0.22%)

, RCKT

Rocket Pharmaceuticals

$24.00 /

-1.18 (-4.69%)

, SGEN

Seattle Genetics

$119.90 /

-0.09 (-0.08%)

, SNY

Sanofi

$50.70 /

-0.44 (-0.86%)

, TAK

Takeda Pharmaceutical

$19.02 /

-0.135 (-0.70%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 08:09
02/19/20
02/19
08:09
02/19/20
08:09
ABBV

AbbVie

$93.60 /

-0.47 (-0.50%)

, ADPT

Adaptive Biotechnologies

$31.75 /

+0.29 (+0.92%)

, AMGN

Amgen

$221.74 /

-1.58 (-0.71%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

-0.0132 (-5.09%)

, ATRA

Atara Biotherapeutics

$14.55 /

+0.3 (+2.11%)

, AZN

AstraZeneca

$49.17 /

+1.3 (+2.72%)

, BLUE

Bluebird Bio

$88.16 /

-0.98 (-1.10%)

, CDNA

CareDx

$27.15 /

+0.48 (+1.80%)

, CDTX

Cidara Therapeutics

$3.08 /

+0.1 (+3.36%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.04 /

+0.06 (+1.20%)

, GMDA

Gamida Cell

$4.76 /

+0.035 (+0.74%)

, GSK

GlaxoSmithKline

$43.55 /

-0.19 (-0.43%)

, HUM

Humana

$372.26 /

-3.815 (-1.01%)

, INCY

Incyte

$79.25 /

+0.83 (+1.06%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$4.85 /

+0.325 (+7.19%)

, MGTA

Magenta Therapeutics

$12.56 /

+0.2 (+1.62%)

, MRK

Merck

$82.46 /

-0.18 (-0.22%)

, NVS

Novartis

$97.21 /

-0.465 (-0.48%)

, PFE

Pfizer

$36.31 /

-0.18 (-0.49%)

, RCKT

Rocket Pharmaceuticals

$25.18 /

+1.18 (+4.92%)

, SGEN

Seattle Genetics

$119.99 /

+1.9 (+1.61%)

, SNY

Sanofi

$51.14 /

+1.21 (+2.42%)

, TAK

Takeda Pharmaceutical

$19.15 /

-0.29 (-1.49%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald » 13:21
01/27/20
01/27
13:21
01/27/20
13:21
CDTX

Cidara Therapeutics

$3.64 /

+0.14 (+4.00%)

As more U.S. coronavirus…

As more U.S. coronavirus cases emerge and death toll rises in China, Cantor Fitzgerald analyst Louise Chen notes that some experts and politicians urge federal officials to declare coronavirus a public health emergency in the U.S. In doing so, CDC can utilize the $85M budget that is allocated to fight this deadly disease, she points out. The analyst believes this coronavirus brings Cidara Therapeutics' Cloudbreak Antiviral Fc Conjugates into the spotlight. The company is developing a universal flu vaccine and the data thus far has been "impressive," Chen contends. The analyst believes the Street "underappreciates" Cidara Therapeutics' Cloudbreak AVCs which could potentially offer a single-dose universal protectant and treatment for influenza and other viral diseases. Chen has an Overweight rating and $8 price target on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Cidara Therapeutics intends to raise $30M in a rights offering » 08:56
01/10/20
01/10
08:56
01/10/20
08:56
CDTX

Cidara Therapeutics

$3.81 /

+0.12 (+3.25%)

Cidara Therapeutics…

Cidara Therapeutics announced its intent to raise $30M through a fully backstopped rights offering. Under the terms of the rights offering, investors as of January 21, 2020 in Cidara's common stock and preferred stock, as well as the holders of Cidara's warrants issued on May 21, 2018, will receive a subscription right entitling them to purchase their pro rata share of the $30M offering amount. The rights offering will be fully backstopped by BVF Partners L.P. and Stonepine Capital, LP, each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed for by other purchasers in the rights offering, for a total of up to $30M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.